Asthma
Conditions
Keywords
Symbicort SMART, budesonide, formoterol, ICS/LABA, Asthma Control Questionnaire, Not optimally controlled asthma
Brief summary
A non-interventional study to explore actual asthma control status in real-life environment and to observe the efficacy after stepped-up to Symbicort SMART or various identical regimens. The study will be implemented by screening asthmatic patients from respiratory clinics to identify those not optimally controlled and required stepping up the controllers to initiate, or to titrate dose of, ICS/LABA including Symbicort.
Interventions
None listed
Sponsors
AstraZeneca
Study design
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Asthma patient who was partly controlled or uncontrolled by previous controllers of ICS only, or low dose ICS plus either LABA, leukotriene modifier or theophylline; or ICS- naïve with severe and persist symptom based on physician's judgment * According to GINA guideline, who need to step up the controller medications, and ICS/LABA to be prescribed based on physician's discretion
Exclusion criteria
* Patients aged not within limitation refer to label information of various product prescribed * Patients who have taken oral corticosteroids within 4 weeks prior to enrollment * Patients with contraindications to prescribed medication
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in ACQ score from baseline to the mean of all available data from the follow up visits | wk 4±1; wk 12~16 |
Secondary
| Measure | Time frame |
|---|---|
| Change in the individual asthma control status & pulmonary function from enrollment | wk 4±1; wk 12~16 |
| Dose/usage of ICS/LABA and relievers & Patient compliance | wk 4±1; wk 12~16 |
| Medical resource utilization | wk 4±1; wk 12~16; 6 month; 12 month |
Countries
Taiwan
Outcome results
None listed